• 四川大學華西醫(yī)院感染性疾病中心（成都，610041）;

【摘要】　目的　 提高對自身免疫性肝病的認識。　方法　 報道一例自身免疫性肝炎/原發(fā)性膽汁性肝硬化重疊綜合征誤診為藥物性肝炎，并綜述相關文獻總結其臨床表現(xiàn)、診斷、治療及預后。　結果　 自身免疫性肝病是一組以肝臟病理損害和肝功能異常為主要表現(xiàn)的自身免疫性疾病，可分為自身免疫性肝炎（autoinmmune hepatitis，AIH）和（primary biliary cirrhosis，PBC）及原發(fā)性硬化性膽管炎（primary sclerosing cholangitis，PSC）。由于無特異性的臨床表現(xiàn)，容易漏診或誤診為藥物性肝炎，診斷主要依靠生化及免疫學檢查。AIH/PBC重疊綜合征的治療目前無成熟經(jīng)驗，主要藥物包括熊去氧膽酸（UDCA）、糖皮質激素和免疫抑制劑等。　結論　 對于不明原因的肝損害患者應做免疫學篩查。

引用本文： 王娟,唐紅. 自身免疫性肝炎/原發(fā)性膽汁性肝硬化重疊綜合征誤診為藥物性肝炎一例. 華西醫(yī)學, 2010, 25(11): 2062-2063. doi: 復制

版權信息： ?四川大學華西醫(yī)院華西期刊社《華西醫(yī)學》版權所有，未經(jīng)授權不得轉載、改編

1. 　Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between aunoimmune hepatitis and primary cholestatic liver disease[J]. Eur J Gastroenterol Hepatol, 2004, 16(6): 585-592.
2. 　姚光弼, 范上達, 廖光杰. 臨床肝臟病學[M]. 上海: 上海科學技術出版社, 2004: 437-454, 483-497.
3. 　賈繼東. 自身免疫性肝病的基本概念和診斷思路[J]. 中華肝臟病雜志, 2005, 13(1): 54.
4. 　溫小鳳, 蔣忠勝. AIH-PBC重疊綜合征的診斷及治療[J]. Chinese Hepatology. 2009, 14(5): 426-427.
5. 　Chazouillères O, Wendum D, Senfaty L, et al. Long tem outcome and response to therapy of primary biliary cirrhosis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406.
6. 　ltakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis[J]. Hepatol Res, 2004, 29(4): 216-212.
  1. 1. 　Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between aunoimmune hepatitis and primary cholestatic liver disease[J]. Eur J Gastroenterol Hepatol, 2004, 16(6): 585-592.
  2. 2. 　姚光弼, 范上達, 廖光杰. 臨床肝臟病學[M]. 上海: 上?？茖W技術出版社, 2004: 437-454, 483-497.
  3. 3. 　賈繼東. 自身免疫性肝病的基本概念和診斷思路[J]. 中華肝臟病雜志, 2005, 13(1): 54.
  4. 4. 　溫小鳳, 蔣忠勝. AIH-PBC重疊綜合征的診斷及治療[J]. Chinese Hepatology. 2009, 14(5): 426-427.
  5. 5. 　Chazouillères O, Wendum D, Senfaty L, et al. Long tem outcome and response to therapy of primary biliary cirrhosis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406.
  6. 6. 　ltakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis[J]. Hepatol Res, 2004, 29(4): 216-212.